Skip to main content

Table 1 Characteristics of studies included in the meta-analysis Study

From: The association between cystatin C and COPD: a meta-analysis and systematic review

AuthorYearStudy designCountryEthnicitySampleSample sizeAssay methodCys C Concentration (mean±SD, mg/L)Subjects(% men)Age (mean±SD or median (range), year)NOS score
CaseControlCaseControlSCOPDAECOPDControl
Qu et al [37]2010Case-controlChinaAsianserum7030ELISASCOPD(70)1.76±0.620.98±0.5162.3/NA/66.764.60±10.50NA63.50±9.206
Rokadia et al [38]2012Cross-sectionalUSACaucasianserum3745264immunonephelometryAll(374)0.978±0.34;Emphysema(120)1.139±0.24;Chronic bronchitis(254)0.902±0.350.883±0.5836.6/49.352.441.18
Sun et al [39]2013Case-controlChinaAsianserum84NAimmunonephelometrySCOPD(30)0.95±0.23; AECOPD(54)1.12±0.26NA70.0/68.5/NA64.17±10.0366.98±8.07NA6
Zhang et al [27]2014Case-controlChinaAsianserum129122immunonephelometrySCOPD(129)0.115±0.050.105±0.03100.0/NA/100.081.78± 6.68NA80.26±6.818
Zhang et al [29]2014Case-controlChinaAsianserum392151immunonephelometryAll(392)1.04±0.21;SCOPD(299)1.03±0.21;AECOPD(93)1.09±0.220.84±0.1896.1/73.1/55.065 (36-86)65 (44-81)63±6.008
Yoshizawa et al [40]2015Case-controlJapanAsianserum10873immunonephelometrySCOPD(108)1.2±0.40.9±0.283.3/NA/49.374.3±7.1NA71.8±7.39
Liu et al [41]2015Case-controlChinaAsianserum13236ELISAAll(132)0.1287±0.0377;SCOPD(60)0.1254±0.0309;AECOPD(72)0.1315±0.04250.1084±0.026752.8/51.7/55.560-6962-7160-687
Zhang et al [42]2015CohortChinaAsianserum9090immunonephelometryAECOPD(90)1.31±0.300.87±0.13NA/78.9/77.8NA63±762±77
Zhou et al [43]2016Case-controlChinaAsianserum168NAimmunonephelometrySCOPD(60)0.94±0.22;AECOPD(108) 1.13±0.25NA70/67.6/NA65.20±10.1067.11±8.11NA6
Ni et al [44]2017Case-controlChinaAsianserum9045immunonephelometryAll(90)0.1409±0.0197;SCOPD(45)0.1339±0.0154;AECOPD(45)0.1478±0.02120.1045±0.020954.4/53.358.1±5.456.9±4.97
Chen et al [45]2017Case-controlChinaAsianserum9520ELISA0.13299±0.011210.10617±0.0213256.8/63.364.04±3.1263.76±2.447
Cui et al [46]2018Case-controlChinaAsianserum15750immunonephelometry1.06±0.410.84±0.2760.5/6073.2±8.270.5 ± 4.77
Selda et al [31]2018Case-controlTurkeyAsianserum12650immunonephelometryAll(126)0.99±0.45;SCOPD(68)1.01±0.56;AECOPD(58)0.97±0.290.47±0.1388.2/82.8/82.064.19±10.665.12±6.9360.12±11.778
Amado et al [28]2018CohortSpainCaucasianserum6518immunonephelometrySCOPD(65)0.97±0.320.88±0.272/NA/5567±7NA67±59
Dickson et al [30]2019Case-controlChinaAsianserum###NAimmunonephelometrySCOPD(362)1.18±0.471;AECOPD(1637)1.21±0.47NA68.5/69.5/NA92.97±9.8372.51±10.27NA7
  1. Abbreviations: COPD Chronic obstructive pulmonary disease, Cys C Cystatin C, NOS Newcastle-Ottawa scale, ELISA enzyme-linked immunosorbent assay, AECOPD acute exacerbation COPD, SCOPD stable COPD